THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Subject: Multiple Sclerosis - PUBLISHED VIA Expert Review of Neurotherapeutics
View Source >>
Sastre-Garriga J, Vila C, Clissold S, Montalban X
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Published via Clinical Therapeutics
Published via Expert Opinion on Biological Therapy
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.
Published via Neurobiology of Disease
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
Published via Neurological Research
Published via Journal of Neurology
Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Published via Expert Review of Neurotherapeutics